An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

Required: HLA-A A*02 positive

HLA-A*02 positive

Required: CTAG1B immunohistochemical staining positive rate ≥20% (≥20%)

The positive rate of NYESO-1 immunohistochemical staining was ≥20%.

Must have received: antineoplastic therapy — first-line

Patients with first-line treatment failure

Cannot have received: antineoplastic drugs and treatments

Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion

Cannot have received: major surgery

Patients who received major surgery...within 4 weeks before entering the trial

Cannot have received: conventional chemotherapy

Patients who received...conventional chemotherapy...within 4 weeks before entering the trial

Cannot have received: large area radiotherapy

Patients who received...large area radiotherapy...within 4 weeks before entering the trial

Cannot have received: immunotherapy

Patients who received...immunotherapy...within 4 weeks before entering the trial

Cannot have received: biological therapy

Patients who received...biological therapy within 4 weeks before entering the trial

Cannot have received: chronic systemic cortisone steroids

Administration of chronic systemic cortisone steroids...within 4 weeks prior to cell therapy.

Cannot have received: hydroxyurea (hydroxyurea)

Administration of...hydroxyurea...within 4 weeks prior to cell therapy.

Cannot have received: immunomodulatory agents (interleukin-2, interferon-α, interferon-γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin)

Administration of...immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy.